Trial Profile
Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Flecainide/modafinil (Primary)
- Indications Narcolepsy
- Focus Adverse reactions; Therapeutic Use
- Sponsors Theranexus
- 28 Oct 2021 Primary endpoint (Efficacy endpoints) has been met, according to Results published in the Movement Disorders.
- 28 Oct 2021 Results published in the Movement Disorders
- 16 Sep 2020 Status changed from active, no longer recruiting to completed according to results presented at the 24th International Congress of Parkinson's Disease and Movement Disorders.